Barclays PLC Relay Therapeutics, Inc. Transaction History

Barclays PLC

$327 Billion
Q2 2024

A detailed history of Barclays PLC transactions in Relay Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 115,278 shares of RLAY stock, worth $753,918. This represents 0.0% of its overall portfolio holdings.

Number of Shares

115,278

Previous 139,996 17.66%

Holding current value

$753,918

Previous $1.16 Million 35.23%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$5.9 - $8.02 $145,836 - $198,238	-24,718 Reduced 17.66%	115,278 $752,000
Q1 2024 May 15, 2024	SELL	$7.5 - $12.07 $1.16 Million - $1.87 Million	-154,789 Reduced 52.51%	139,996 $1.16 Million
Q4 2023 Feb 15, 2024	BUY	$6.01 - $11.48 $476,689 - $910,547	79,316 Added 36.81%	294,785 $3.25 Million
Q3 2023 Nov 07, 2023	SELL	$8.24 - $12.97 $772,170 - $1.22 Million	-93,710 Reduced 30.31%	215,469 $1.81 Million
Q2 2023 Aug 03, 2023	BUY	$9.99 - $18.27 $1.15 Million - $2.1 Million	114,709 Added 58.99%	309,179 $3.88 Million
Q1 2023 May 04, 2023	SELL	$15.0 - $22.76 $1.16 Million - $1.76 Million	-77,369 Reduced 28.46%	194,470 $3.2 Million
Q4 2022 Feb 13, 2023	BUY	$14.16 - $24.02 $1.72 Million - $2.92 Million	121,628 Added 80.97%	271,839 $4.06 Million
Q3 2022 Nov 03, 2022	BUY	$18.07 - $31.37 $1.45 Million - $2.52 Million	80,404 Added 115.18%	150,211 $3.36 Million
Q2 2022 Aug 12, 2022	SELL	$13.31 - $34.88 $83,333 - $218,383	-6,261 Reduced 8.23%	69,807 $1.17 Million
Q1 2022 May 16, 2022	BUY	$20.26 - $32.36 $1.54 Million - $2.46 Million	76,068 New	76,068 $2.28 Million

Others Institutions Holding RLAY

# of Institutions

183

Shares Held

127M

Call Options Held

1.7K

Put Options Held

18K

View Full List

About Relay Therapeutics, Inc.

Ticker RLAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 120,219,000
Market Cap $786M
Description
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...

More about RLAY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account